Novo Nordisk Slashes Wegovy & Ozempic List Prices by Up to 50% — But Analysts Say It Won’t Dent Lilly’s Lead

Novo Nordisk slashes list prices for Wegovy, Ozempic & Rybelsus to $675/month starting Jan 2027—50% cut for Wegovy. Helps high-deductible plans, but BofA sees little threat to Eli Lilly’s GLP-1 lead.